Selection and evaluation of patients for cardiac transplantation;Selección y evaluación de pacientes candidatos a trasplante cardíaco

Revista Espanola de Cardiologia

Volumn 52, Issue 8, 1999, Pages 604-616

  Castro, Pablo F ^a   Bourge, Robert C ^b   Jalil, Jorge E ^b   Martínez, José A ^b  

^a NONE   (Chile)

^b NONE

Author keywords

Heart failure; Patients; Selection; Transplantation

Indexed keywords

CONGESTIVE HEART FAILURE; DRUG CONTRAINDICATION; ECONOMICS; HEART TRANSPLANTATION; HUMAN; PATIENT SELECTION; REVIEW;

HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; PATIENT SELECTION;

EID: 0033173178     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(99)74976-6     Document Type: Article

References (119)

1. Guidelines of the evaluation and Management of Heart Failure Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committe on Evaluation and Management of Heart Failure). ACC/AHA TASK FORCE REPORT. J Am Coll Cardiol 1995; 26: 1.376-1.398.
2. Castro P, Bourge RC, Foster RE. Evaluation of hibernating myocardium and coronary artery revascularization for the patient with ischemic cardiomyopathy. Am J Med 1998; 104: 69-77.
3. Stevenson LW, Fowler MB. Schoeder JS, Stevenson WG, Dracup KA, Fond V. Poor survival of patients with idiopathic cardiomyopathy considered too well for transplantation. Am J Med 1987; 83: 871-876.
4. Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol 1990; 65: 903-908.
5. Wilson JR, Rayos G, Yeok TK, Gothard P, Bak K. Dissociation between exertional symptoms and circulatory function in patients with heart failure. Circulation 1995; 92: 47-53.
6. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1.429-1.435.
7. Stevenson LW, Hamilton MA, Tillisch JH, Moriguchi JD, Kobashigawa JA, Creaser JA et al Decreasing survival benefit from cardiac transplantation for outpatients as the waiting list lengthens. J Am Coll Cardiol 1991; 18: 919-925.
8. aed.). Nueva York: Churchill Livingstone, 1993; 461.
9. Carabello BA. Timing of surgery in mitral and aortic stenosis. Cardiol Clin 1991; 9: 229-238.
10. a ed.). Nueva York: Churchill Livingstone, 1993; 527.
11. Zile MR. Chronic aortic and mitral regurgitation: choosing the optimal time for surgical correction. Cardiol Clin 1991; 9: 239-253.
12. Bonow RO, Borer JS, Rosing DR, Henry WL, Pearlman AS, McIntosh CL et al. Preoperative exercise capacity in symptomatic patients with aortic regurgitation as a predictor of postoperative left ventricular function and long-term prognosis. Circulation 1980; 62: 1.280-1.290.
13. Bonow RO, Picone AL, McIntosh CL, Jones M. Rosing DR, Maron BJ et al. Survival and functional results after valve replacement for aortic regurgitation from 1976 to 1983: impact of preoperative left ventricular function. Circulation 1985; 72: 1.244-1.256.
14. Lytle BW. Impact of coronary artery disease on valvular heart surgery. Cardiol Clin 1991; 9: 301-314.
15. Boiling SF, Pagani FD, Deeb GM. Bach DS. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg 1998; 115: 381-386.
16. Alvarez R, Cohen S, Chamorro G, Irarrázabal MJI, Rodríguez JA, Casanegra P et al. La prueba de esfuerzo cardiopulmonar en la evaluación preoperatoria de pacientes con insuficiencia valvular severa. Rev Chilena Cardiol 1997; 16: 154.
17. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1997; 28: 1.458-1.453.
18. Levine TB, Levine AB, Keteyian SJ, Narins B, Lesh M. Reverse remodeling in heart failure with intensification of vasodilatador therapy. Clin Cardiol 1997; 20: 697-702.
19. Levine TB, Levine AB, Goldberg D, Narins B, Goldstein S, Lesch M. Impact of medical therapy on pulmonary hypertension in patients with congestive heart failure awaiting cardiac transplantation. Am J Cardiol 1996; 78: 440-443.
20. Pitt B, Segal R, Martínez FA, Meurers G, Cowley AJ, Thomas I et al. Randomised trial of Iosartan versus captopril in patients over 65 with heart failure. Lancet 1997; 349: 745-752.
21. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I et al. Double-blind, placebo-controlled study of effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial: Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996; 94: 2.793-2.799.
22. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-380.
23. CIBIS II investigators and Commmittees. The cardiac insufficiency bisoprolol study (CIBIS II): a randomised trial. Lancet 1999; 353: 9-13.
24. Costanzo MR, Augustine S, Bourge R, Bristow M, O'Connell JB, Driscoll D et al. Selection and treatment of candidates for Heart Transplantation. Circulation 1995; 92: 3.593-3.612.
25. a ed.). Filadelfia: WB Saunders Company, 1996; 48: 360-367.
26. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector Y et al, for the V-HeFT VA Cooperative Studies Group: Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhytmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993; 87 (Supl 4): 16.
27. Lucas C, Johnson W, Flavell C, Fonarow G, Hamilton M, Creaser J et al. Freedom from congestion at one month predicts good two-year survival for class IV heart failure. Circulation 1996; 94 (Supl 1): 193.
28. Morris CK, Ueshima K, Kawaguchi T, Hideg A, Froelicher VF. The prognostic value of exercise capacity: a review of the literature. Am Heart J 1991; 122: 1.423-1.431.
29. Chang JA, Froelicher VF. Clinical and exercise test markers of prognosis in patients with stable coronary artery disease. Curr Prob Cardiol 1994; 19: 533-588.
30. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 1987; 59: 634-638.
31. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83: 778-786.
32. Bugueño C, Jalil JE, Godoy I, Martínez A, Chamorro G, Corbalán R et al. Prueba de esfuerzo cardiopulmonar en pacientes con insuficiencia cardíaca crónica. Rev Med Chile 1995; 123: 571-579.
33. Haywood GA, Rickenhacher PR, Trindade PY, Gulleslad L, Jiang JP, Schroeder JS et al. Analysis of deaths in patients awaiting heart transplantation: impact on patient selection criteria. Heart 1996; 75: 455-462.
34. Saxon LA, Stevenson WG, Middlekauff HR, Fonarow G. Woo M, Moser D et al. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1993; 72: 62-65.
35. Myers J, Gullestad L. The role of exercise testing and gas-exchange measurement in the prognostic assessment of patients with heart failure. Curr Opin Cardiol 1998: 13: 145-155.
36. Stelken AM, Younis LT, Jenninson SH, Miller DD, Miller LW, Shaw LJ et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol 1996; 27: 345-352.
37. Osada N, Chaitman BR, Miller LW, Yip D, Cicheck MB, Woldford TL et al Cardiopulmonary exercise testing identities low risk patients with heart failure and severely impaired exercise capacity considered for heart transplantation. J Am Coll Cardiol 1998; 31: 577-582.
38. Stevenson LW, Steimle AE, Fonarow G, Kermani M, Kermani D, Hamilton MA et al Improvement in exercise capacity of candidates awaiting heart transplantation. J Am Coll Cardiol 1995; 25: 163-170.
39. Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol 1988; 62: 25A-30A.
40. Gradman A, Deedwania P, Cody R, Massie B, Packer M, Pitt B et al. Predictors of total mortality and sudden death in mild to moderate heart failure: Captopril Digoxin Study Group. J Am Coll Cardiol 1989; 14: 564-570.
41. Unverferth DV, Magorien RD, Moeschberger ML. Baker PB, Fetters JK, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 1984; 54: 147-152.
42. Schwarz F, Mall G, Zebe H, Schmitzer E, Manthey J, Scheurlen H et al. Determinants of survival in patients with congestive cardiomyopathy: quantitative morphologic findings and left ventricular hemodynamics. Circulation 1984; 70: 923-928.
43. Cohn JN, Archibald DG, Francis GS, Ziesche S, Franciosa JA, Harston WE et al. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of pre-randomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Circulation 1987; 75 (Supl 4) (parte 2): 49-54.
44. Stevenson LW, Tillisch JH, Hamilton M, Luu M, Chelimsky-Fallick C, Moriguchi J et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990; 66: 1.348-1.354.
45. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F et al. A comparison of enalapril with Hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
46. Nagaoka H, Isobe N, Kubota S, Iizuka I, Imai S, Susuki T et al. Myocardial contractile reserve as prognostic determinant in patients with idiopathic dilated cardiomyopathy without overt heart failure. Chest 1997; 111: 344-350.
47. Di Salvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995; 25: 1.143-1.153.
48. Juilliere Y, Barbier G, Feldman A, Grentzinger N, Danchin N, Cherrier F. Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy. Eur Heart J 1997; 18: 276-280.
49. Fuster V, Gersch BJ, Guiliani ER, Tajik AJ, Branderburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol 1981; 47: 525-531.
50. Madsen BK, Hansen JF, Stokholm KH, Brons J, Husum D, Martesen LS. Chronic congestive heart failure. Description and survival of 190 consecutive patients with diagnosis of chronic congestive heart failure based on clinical signs and symptoms. Eur Heart J 1994; 15: 303-310.
51. Kelly TL, Cremo R, Nielson C, Shabeiti R. Prediction of outcome in late stage cardiomyopathy. Am Heart J 1990; 119: 1.111-1.121.
52. Stevenson LW, Couper G, Natterson B, Fonarow G, Hamilton MA, Woo M et al. Target heart failure populations for newer therapies. Circulation 1995; 92 (Supl 2): 174-181.
53. Cleland JGF, Bristow M, Erdmann E, Remme WJ, Swedberg K, Waggtein F. Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J 1996; 17: 1.629-1.639.
54. Grandman AH, Deewania PC. Predictors of mortality in patients with heart failure. Cardiol Clin 1994; 12: 25-35.
55. Chomsky DB, Lang CC, Rayos GH, Shyr Y, Yeoh TK. Haemodynamic exercise testing: a valuable tool in the selection of cardiac transplant candidates [resumen]. Circulation 1996; 94 (Supl 1): 290.
56. Roul G, Moulichon ME, Bareiss P, Greis P, Koegler A, Sacrez J et al. Prognostic factors of chronic heart failure in NYHA class II or III: value of invasive exercise haemodynamic data. Eur Heart J 1995; 16: 1.387-1.398.
57. Mancini D, Katz, Donchez L, Aaronson K. Coupling of hemodynamic measurements with oxygen consumption during exercise does not improve risk stratification in patients with heart failure. Circulation 1996; 94: 2.492-2.496.
58. O'Connor CM, Anderson SA, Meese RB. Clinical determinants of outcome in advanced heart failure: insights from the PRAISE trial [resumen]. J Am Coll Cardiol 1997; 129: 246A.
59. Pozzoli M, Traversi E, Cioffi G, Stenner R, Sanarico M, Tavazzi L. Loading manipulations improve the prognostic value of doppler evaluation of mitral How in patients with chronic heart failure. Circulation 1996; 95: 1.222-1.230.
60. Aaronson KD, Schwartz JS, Chen T, Wong K, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997; 95: 2.660-2.667.
61. Stevenson WG, Middlekauf HR, Stevenson LW, Saxon LA, Woo MA, Moser D. Significance of aborted cardiac arrest and sustained ventricular tachycardia in patients referred for treatment of advanced heart failure. Am Heart J 1992; 124: 123-130.
62. Cleland JGF, Dargie HJ, Ford I. Mortality in heart failure: clinical variables of prognostic value. Br Heart J 1987; 58: 572-582.
63. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73: 257-267.
64. Yusuf S. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
65. Pernenkil R, Vinson JM, Shah AS, Beckham V, Wittenberg C, Rich MW. Course and prognosis in patients > 70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. Am J Cardiol 1997; 79: 216-219.
66. Nolan J, Batin PD, Andrews R, Lindsay ST, Brooksby P, Muller M et al. Prospective study of heart variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation an assessment of risk trial. Circulation 1988; 98: 1.510-1.516.
67. Nul DR, Doval HC, Grancelli HO, Varini SD, Soifer S, Perrone SV et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de estudio de la supervivencia en la insuficiencia cardfaca en Argentina. Grupo de estudios multicéntricos en Argentina. J Am Coll Cardiol 1997; 29: 1.199-1.205.
68. Madsen BK, Keller N, Christiansen E, Christiansen NJ. Prognostic value of plasma catecholamines, plasma renin activity, and plasma atrial natriuretic peptide at rest and during exercise in congestive heart failure: comparison with clinical evaluation, ejection fraction, and exercise capacity. Cardiac Failure 1995; 1: 207-216.
69. Batin PD, Wickens M, McEntegart D. The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 1995; 16: 1.613-1.618.
70. Rockman HA, Juneau C, Chaterjje K, Rouleau J. Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1989; 64: 1.344-1.348.
71. Cohn J, Levine TB, Olivari MT. Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure. N Engl J Med 1984; 311: 819-823.
72. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1.730-1.736.
73. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996; 94: 690-697.
74. Brouwer J, Van Vedhuisen D, Man in't Veld AJ, Haaksma J, Dijk WA, Visser KR. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. J Am Coll Cardiol 1996; 28: 1.183-1.189.
75. Fauchier L, Babuty D, Cosnay P, Autret ML, Fauchier JP. Heart rate variability in idiopathic dilated cardiomyopathy: characteristics and prognostic value. J Am Coll Cardiol. 1997; 30: 1.009-1.014.
76. Yi G, Goldman JH, Keeling PJ, Reardon M, McKenna WJ, Malik M. Heart rate variability in idiopathic dilated cardiomyopathy: relation to disease severity and prognosis. Heart 1997; 77: 108-114.
77. Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre G et al. Plasma endothelin-1 is a strong prognostic marker in chronic heart failure. Eur Heart J 1997; 18: 254-258.
78. Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive haemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996; 27: 633-641.
79. Cody RJ, Naas GJ, Binkley PF, Capers O, Kelly R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504-509.
80. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-241.
81. Ferrari R, Bachetti T, Confortini R. Tumor necrosis factor soluble receptors in patients with various degrees of heart failure. Circulation 1995; 92: 1.479-1.486.
82. Cleland JGF, Cowburn PJ, Morgan K. Neuroendocrine activation after myocardial infarction: causes and consequences. Heart 1996; 76 (Supl 3): 53-59.
83. Hall C, Rouleau JL, Moye L, De Champlain J, Bichet D, Klein M et al. N-terminal proatrial natriuretic factor: an independent predictor of long-term prognosis after myocardial infarction. Circulation 1994; 89: 1.934-1.942.
84. Olshausen KV, Steinen U, Schawartz F, Kubler W, Mejer J. Long term prognostic significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1988; 61: 146-151.
85. Turrito G, Ahuja RK, Caref EB, El Sherif N. Risk stratification for arrhythmic events in patients with nonischaemic dilated cardiomyopathy and nonsustained ventricular tachycardia: role of programmed ventricular stimulation and the signal averaged electrocardiogram. J Am Coll Cardiol 1994; 24: 1.523-1.528.
86. Menertz T, Treese N, Kasper W. Determinants of prognosis in idiopathic dilated cardiomyopathy as determined by programmed electrical stimulation. Am J Cardiol 1985; 56: 337-341.
87. Milner PG, DiMarco JP, Lerman BB. Electrophysiological evaluation of sustained ventricular tachyarrhythmias in idiopathic dilated cardiomyopathy. PACE 1988; 11: 562-568.
88. Stevenson WG, Stevenson LW, Weiss J, Tillisch JH. Inducible ventricular arrhythmias and sudden death during vasodilator therapy of severe heart failure. Am Heart J 1988; 116: 1.447-1.454.
89. Das SK, Morady F, DiCarlo L Jr, Baerman J, Krol R, De Buitleir M et al. Prognostic usefulness of programmed ventricular stimulation in idiopathic dilated cardiomyopathy without symptomatic ventricular arrhythmias. Am J Cardiol 1986; 58: 998-1.000.
90. Middlekauf HR, Stevenson WG, Warner-Stevenson L, Saxon LA. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol 1993; 21: 110-116.
91. Heroux AL, O'Sullivan EJ, Kao WG, Liao Y, Johnson MR, Mullen GM et al. Should cardiac transplantation be a treatment option after 65 years of age? J Heart and Lung Transplant 1992; 11: 220.
92. Olivari MT, Antolick A, Kaye MP, Jamieson SW, Ring WS. Heart transplantation in elderly patients. J Heart Lung Transplant 1988; 7: 258-264.
93. Frazier OH, Macris MP, Duncan JM, Van Buren CT, Cooley DA. Cardiac transplantation in patients over 60 years of age. Ann Thorac Surg 1990; 45: 129-132.
94. Amrein C, Vulser C, Farge D, Guillemain R, Dreyfus G, Couetil JP et al. Is heart transplantation a valid therapy in elderly patients? Transplant Proc 1990; 22: 1.454-1.456.
95. Muñoz E, Lonquist JL, Radovancevic B, Baldwin RT, Ford S, Duncan JM et al. Long-term results in diabetic patients under-going heart transplantation. J Heart Lung Transplant 1992; 11: 943-949.
96. Ladowski JS, Kormos RL, Uretsky BF, Griffith BP, Armitage JM, Hardesty RL. Heart transplantation in diabetic recipients. Transplantation 1992; 49; 303-305.
97. Faglia E, Favales F, Mazzola, Pizzi G, De Maria R, Mangiavacchi M et al. Heart transplant in mildly diabetic patients. Diabetes 1990; 39: 740-742.
98. Badelino MM, Cavarocchi NC, Narins B, Jessup M, Alpern JB, McClurken JB et al. Cardiac transplantation in diabetic patients. Transplant Proc 1990; 22: 2.384-2.388.
99. Rhenman MJ, Rhenman B, Icenogle T, Christensen R, Copelan J. Diabetes and heart transplantation. J Heart Transplant 1988; 7: 356-358.
100. Kirklin JK, Naftel DC, Kirklin JW, Blackstone EH, White-Williams C, Bourge RC. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant 1988; 7: 331-336.
101. Kormos RL, Thompson M, Hardesty RL, Griffith BP, Trento A, Uretsky BF et al. Utility of perioperative right heart catheterization data as a predictor of survival after heart transplantation [resumen]. J Heart Transplant 1986; 5: 391.
102. Erickson KW, Costanzo-Nordin MR, O'Sullivan EJ, Johnson MR, Zucker MJ, Pifarre R et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant 1990; 9: 526-537.
103. Almenar L, Vicente JL, Torregrosa S, Osa A, Martínez-Dolz L, Gómez-Plana J, Varela F, Palencia M, Caffarena JM, Algarra F. Variables predictoras de mortalidad precoz tras el trasplante cardíaco ortotópico en adultos. Rev Esp Cardiol 1997; 50: 628-634.
104. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potent al reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992; 19: 48-54.
105. O'Connell JB, Bourge RC, Costanzo-Nordin M, Driscoll DJ, Morgan JP, Rose EA et al. Cardiac transplantation: recipient selection, donoi procurement, and medical follow-up: a statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology, Am Heart Association. Circulation 1992; 86: 1.061-1.079.
106. Bourge RC, Naftel DC, Costanzo-Nordin MR, Kirklin JK, Young JB, Kubo SH et al, for the Transplant Cardiologists Research Database Group. Pretransplantation risk factors for death after heart transplantation: a multi-institutional study. J Heart Lung Transplant 1993; 12: 549-562.
107. 1 in the pre transplantation evaluation of heart failure patients with significant pulmonary hypertension. J Heart Lung Transplant 1992; 11 (parte 1): 716-723.
108. Palevsky HI, Long W, Crow J, Fishman AP. Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension. Circulation 1990; 82: 2.018-2.026.
109. Kieler-Jensen N, Milocco I, Ricksten SE. Pulmonary vasodilation after heart transplantation: a comparison among prostacyclin, sodium nitroprusside, and nitroglycerin on right ventricular function and pulmonary selectivity. J Heart Lung Transplant 1993; 12: 179-184.
110. Haywood GA, Sneddon JF, Bashir Y, Jennison SH, Gray HH, McKenna WJ. Adenosine infusion for the reversal of pulmonary vasoconstriction in biventricular failure: a good test but a poor therapy. Circulation 1992; 86: 896-902.
111. Semigran JM, Cockrill BA, Kacmarek K. Nitric oxide is an effective pulmonary vasodilator in cardiac transplant candidates with pulmonary hypertension. J Heart Lung Transplant 1993; 12 (Supl): 67.
112. Kieler-Jensen N, Ricksten SE, Stenqvist O, Bergh CH, Lindelov B, Wennmalm A et al. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 1994; 13: 366-375.
113. Light RW, George RB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med 1983; 143: 429-433.
114. Loria KM, Salinger MH, Frohlich TG, Arentzen CE, Alexander JC Jr, Anderson RW. Right lower lobectomy for pulmonary infarction before orthotopic heart transplantation. J Heart Lung Transplant 1991; 10: 325-328.
115. DiSesa VJ, Sloss LJ, Cohn LH. Heart transplantation for intractable prosthetic valve endocarditis. J Heart Transplant 1990; 91: 142-143.
116. Dillon TA, Sullivan M, Schatzlein MH, Peterson AC, Scheeringa RH, Clark WR Jr et al. Cardiac transplantation in patients with preexisting malignancies. Transplantation 1991; 52: 82-85.
117. Gries W, Farkas D, Winters GL, Costanzo-Nordin MR. Giant cell myocarditis: first report of disease recurrence in the trasplanted heart. J Heart Lung Transplant 1992; 11 (parte 1 ): 370-374.
118. Hosenpud JD, Uretsky BF, Griffith BP, O'Connell JB, Olivari MT, Valanline HA. Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of multicenter survey. J Heart Lung Transplant 1990; 9: 346-350.
119. O'Connell JB, Dee GW, Goldemberg IF, Starling RC, Mudge GH, Agustine SM et al. Results of heart transplantation for active lymphocytic myocarditis. J Heart Lung Transplant 1990; 9: 351-356.